Labcorp Holdings (LH) Cash & Equivalents (2009 - 2026)

Labcorp Holdings has disclosed Cash & Equivalents across 18 years of filings, most recently posting $981.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $981.1 million, up 165.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $981.1 million (up 165.59% YoY), and the FY2025 annual result was $532.3 million, down 64.95% from the prior year.
• Cash & Equivalents came in at $981.1 million for Q1 2026 at Labcorp Holdings, up from $532.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.9 billion in Q2 2023 to a low of $99.3 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $598.1 million (2025), against an average of $773.6 million.
• Across the five-year window, Cash & Equivalents slumped 86.27% in 2024 and surged 272.0% in 2025, its largest moves.
• Labcorp Holdings' Cash & Equivalents stood at $320.6 million in 2022, then soared by 67.44% to $536.8 million in 2023, then surged by 182.92% to $1.5 billion in 2024, then slumped by 64.95% to $532.3 million in 2025, then surged by 84.31% to $981.1 million in 2026.
• The last three Cash & Equivalents figures came in at $981.1 million (Q1 2026), $532.3 million (Q4 2025), and $598.1 million (Q3 2025), per Business Quant data.